Weakening Rupee Raises Pharmaceutical Margins, but Increasing Costs Moderate Benefits

India's Pharmaceutical Sector Rides Weakening Rupee

A weakening rupee has become a near-term tailwind for India's pharmaceutical sector, lifting export realisations, but industry executives warn that rising input costs and broader macro pressures are increasingly diluting the gains.

While rupee depreciation is negative for drugmakers that primarily rely on the domestic market, the biggest beneficiaries are companies with high export exposure, particularly US-focused generic drugmakers, large formulation players, and contract research and manufacturing firms where dollar revenues significantly outweigh import-linked costs.

The rupee has depreciated about 6.5-7 percent against the US dollar in 2026 so far, with most of the decline occurring over the past two to three months, reflecting global volatility and capital outflows.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Aurobindo Pharma's CFO Santhanam Subramanian quantified the impact of the rupee depreciation at the company's recent earnings call, stating that for a 1 percent INR depreciation against the dollar, EBITDA increases by around Rs 100 crore.

The math is straightforward. Pharmaceutical companies largely earn in dollars while incurring a significant portion of their costs in rupees, allowing currency depreciation to inflate margins and reported profits.

Estimates suggest a 7 percent rupee fall can lift revenues by 3-5 percent and EBITDA by up to 15 percent for export-heavy companies.

Industry executives acknowledge the benefit of the rupee depreciation. Lupin Global CFO Ramesh Swaminathan noted that it can offset pricing pressure in global markets, while Alembic Pharma Managing Director Pranav Amin said the effect is broadly neutral at current levels.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

However, the upside is far from linear. Executives caution that currency gains are increasingly being offset by a sharp rise in raw material and logistics costs, much of which is also dollar-linked.

Subramanian flagged this directly, stating that freight cost has gone significantly high and solvent prices have gone by 2.7X, while raw material prices are also going up. Achin Gupta, global CEO and MD of Cipla, pointed to the industry's underlying exposure, saying that while they have some kind of natural hedge because they sell in dollars, they also buy a lot of goods in dollars.

The key risk is no longer currency loss, but rising input costs. Gupta warned that prolonged volatility will eventually reflect in margins, making the impact uneven. Companies with higher import dependence or significant hedging are less likely to benefit, as rising costs eat into gains from currency translation.

The longer-term macro picture also remains a concern. Swaminathan cautioned that while exporters gain tactically, sustained depreciation is not desirable. It cuts both ways, though they get this benefit, from a long-term stability perspective, he would rather prefer stable rates.

He added that rupee weakness can be inflationary and deter foreign capital flows, especially given India's trade deficit and current account pressures.